2021 Annual Meeting On-Demand: Cellular Therapy/Biotherapies Sessions


Interested in all sessions Cellular Therapy/Biotherapies? Then this is the package for you. We have also thrown in a couple of additional sessions you might also find interesting.

The package includes 22 sessions (1 in Spanish with English subtitles available) which provide you the opportunity to earn up to 16 continuing education credits for physicians or California Nurse contact hours; 23 general credit, or, 23 California Lab Personnel or Florida Lab Personnel contact hours.

Purchase of this package includes the on-demand recording and a downloadable MP3 audio file (in the original recorded language) for each session. Closed captioning in Spanish and English is also available for most sessions. Some speaker handouts may be available, but in general, presentation handouts are not available/included.

If purchasing these sessions separately it would cost $430/$535 (member/nonmember).

Access is available through December 31, 2023 so purchase this package today.

Planning Committee Disclosures

Standard: $249.00
Members: $199.00

Products

AM21-43: Histocompatibility Cases in Hematopoietic Stem Cell Transplantation (HSCT): HLA and Beyond

Preview Available

AM21-43: Histocompatibility Cases in Hematopoietic Stem Cell Transplantation (HSCT): HLA and Beyond

Oct 19, 2021 2:30pm ‐ Oct 19, 2021 3:30pm

Credits: None available.

Histocompatibility in HSCT is more than just identifying a 10/10 HLA-matched donor. Have you ever wondered about how HLA-DPB1 (DP) is different to other HLA loci and why we use different terms like “permissive” and “nonpermissive mismatches”? Ever wanted a (very) basic introduction to killer cell immunoglobulin-like receptor (KIR) and how some places use KIR typing in donor selection? And how about the different types of donor chimerism and their clinical significance when it is not a straightforward 100% chimerism result?

In this session, we will bring a case-based approach in highlighting key teaching points on some of these aspects of histocompatibility. Don’t worry if you do not have prior knowledge; we will provide the introductions. This session is categorized as “Intermediate” only because we going beyond the basics of HLA.
This session is an extension of and inspired by feedback from last year’s session “A Step Above the Basics of HLA for Apheresis/Transfusion Practitioners”.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Speaker(s):
Members: $20.00
Standard: $25.00

AM21-46: Oral Abstract Session -- Transfusion Medicine and Cellular Therapy Innovation

Preview Available

AM21-46: Oral Abstract Session -- Transfusion Medicine and Cellular Therapy Innovation

Oct 19, 2021 3:45pm ‐ Oct 19, 2021 4:45pm

Credits: None available.

Oral abstract session focused on Transfusion Medicine and Cellular Therapy Innovation.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator(s):
  • Thomas Gniadek, MD, PHD, University of Chicago (NorthShore) Pathology
  • Dr. Mary Berg, MD, Professor of Clinical Practice, Pathology Medical Director, Transfusion Services, University of Colorado
Speaker(s):
Members: $20.00
Standard: $25.00

AM21-48: Oral Abstract Session -- Innovation in Apheresis and other Therapeutic Approaches

Preview Available

AM21-48: Oral Abstract Session -- Innovation in Apheresis and other Therapeutic Approaches

Oct 19, 2021 6:00pm ‐ Oct 19, 2021 7:00pm

Credits: None available.

Oral abstract session focused on Innovation in Apheresis and other Therapeutic Approaches.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator(s): Speaker(s):
  • John Markantonis, DO, Department of Pathology, University of Texas Southwestern Medical Center
  • Jenna Wade, MD, Emory University School of Medicine
  • Hollie Reeves, DO, University Hospitals Cleveland Medical Center, Department of Pathology
  • Xiaowu Wu, MD, US Army Institute of Surgical Research
Members: $20.00
Standard: $25.00

AM21-49: Tips and Tools to Overcome Challenges and Negotiate Partnerships for Biotherapy Trials

Preview Available

AM21-49: Tips and Tools to Overcome Challenges and Negotiate Partnerships for Biotherapy Trials

Oct 19, 2021 6:00pm ‐ Oct 19, 2021 7:00pm

Credits: None available.

This program encompasses the experiences from two institutions after facing challenging opportunities of becoming partners with sponsors or manufacturers and principal investigators in order to provide support for a particular study or research project.

The presenters will share institutional and personal experiences in the recent past and will provide smart and practical solutions to overcome issues and challenges for those institutions whom are requested to participate and being able to support cutting edge science and its applications in the clinical setting.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator(s): Speaker(s):
Members: $20.00
Standard: $25.00

AM21-52: Financial Challenges in the Age of Cell and Gene Therapies

Preview Available

AM21-52: Financial Challenges in the Age of Cell and Gene Therapies

Oct 19, 2021 7:15pm ‐ Oct 19, 2021 8:15pm

Credits: None available.

Cell and gene therapies offer unprecedented hope to a growing number of patients. In the treatment of refractory/relapsed malignancy, a single dose may be lifesaving. Payment models may threaten the commercial viability of these therapies. Incremental cost effectiveness analyses have supported manufacturers’ high retail prices for these agents. Payers, on the other hand, are hesitant to pay for such an expensive agent when the benefit may be enjoyed by a competitor to insurance churn. Patients are unlikely to be able to cover such high-cost therapies out of pocket. Operational challenges are also a threat to successful implementation of these therapies. Commercialization of these agents has exposed uncompensated effort throughout the procurement cycle. This session aims to highlight different perspectives on financial challenges of cell and gene therapies and prompt the investigation of innovative solutions.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator(s): Speaker(s):
Members: $20.00
Standard: $25.00

AM21-53: Future Trends in Cell & Gene Therapy: Developments in the Field of Personalized Medicine

Preview Available

AM21-53: Future Trends in Cell & Gene Therapy: Developments in the Field of Personalized Medicine

Oct 19, 2021 9:00pm ‐ Oct 19, 2021 10:00pm

Credits: None available.

This session will focus on future trends in the field of Cell and Gene Therapy and Personalized Medicine. Some of the topics to be discussed include cell therapies, genetically engineered cells, and gene editing technology. Where do we see an increase in Cell & Gene Therapy and what clinical indications? What is developing in the field of personalized medicine that will bring on improvements in Healthcare and how will these improvements affect Healthcare economics? Even with the high cost of these therapies we may see a benefit financially. This session will consist of innovators in the field of Cell and Gene Therapy. Besides short presentations it will include a lively debate as to where the field is headed.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator(s): Speaker(s):
Members: $20.00
Standard: $25.00

AM21-76: The Stop/Go Signals for B Cells Responses and Alloimmunization

Preview Available

AM21-76: The Stop/Go Signals for B Cells Responses and Alloimmunization

Oct 19, 2021 9:00pm ‐ Oct 19, 2021 10:00pm

Credits: None available.


Alloimmunization to transfused products remains a major barrier to safe and efficacious transfusions. Understanding the cues and signals responsible for triggering antibody responses to transfused cells can help to identify potential alloimmunization biomarkers and novel therapeutic targets to prevent and even reverse alloimmunization. In this session, we will describe recent studies on the use of advanced imaging and cell engineering approaches that have led to visualization of leukocyte interactions during an immune response to transfused products, identifying key cell types in driving/stopping alloantibody immune responses. We will also discuss the role of hemolysis in giving a go/no go signal to B cells to differentiate into antibody producing plasma cells in transfused patients with sickle cell disease and describe candidate heme-binding drugs for inhibition of B cell responses for prevention of alloimmunization in sickle cell disease.

Speaker(s):
  • Dr. Sean Stowell, MD, PhD, Associate Medical Director, Brigham and Women's Hospital Transfusion Service Medical Director, Brigham and Women's Hospital Apheresis Service Associate Director, National Center for Functional Glycomics
  • Dr. Karina Yazdanbakhsh, PhD, Executive Director of Research, New York Blood Center
Members: $20.00
Standard: $25.00

AM21-82: Ask the FDA and CMS/CLIA

Preview Available

AM21-82: Ask the FDA and CMS/CLIA

Oct 19, 2021 9:00pm ‐ Oct 19, 2021 10:00pm

Credits: None available.


This annual event provides an opportunity for FDA and CMS/CLIA representatives to respond to member questions and present the agency's current thinking on policies, regulations, guidance documents and inspection programs that are relevant to the oversight of blood and HCT/P programs. Questions for the session are submitted in advance to regulatory@aabb.org. Identify the regulation or recommendation of interest, the specific issue or concern, and any background information, suggestions or proposed solutions to best illustrate your perspective.

Moderator(s): Speaker(s):
Standard: Free
Members: $0.00

AM21-83: Ask the Standards

Preview Available

AM21-83: Ask the Standards

Oct 19, 2021 9:00pm ‐ Oct 19, 2021 10:00pm

Credits: None available.

Presentations will be given by the chairs of the Cellular Therapy Standards and Immunohematology Reference Laboratories Standards Committees. Questions for the discussion are to be submitted by September 1st via email to standards@aabb.org.

Moderator(s): Speaker(s):
Members: $20.00
Standard: $25.00

AM21-86: AABB-ISCT Joint Working Group Project Updates

Preview Available

AM21-86: AABB-ISCT Joint Working Group Project Updates

Oct 19, 2021 9:00pm ‐ Oct 19, 2021 10:00pm

Credits: None available.

In 2014, executive leadership at AABB and ISCT agreed to establish a joint working group (WG) for the purpose of identifying issues common to both organizations in the cellular therapy (CT) arena and exploring advocacy issues on which both organizations can collaborate. The WG has been involved in several projects since then. This session will provide updates on two of the current projects executed by two teams of experts recruited through the WG.

Project 1: Considerations for the Establishment of a CT Product Stability Program

The goals of the project are to:

  • educate the community regarding considerations for CT stability programs
  • create reference documents/communication materials to help with the design of a stability program for hematopoietic stem/progenitor cell products

Project 2: Establishment of a GTP interpretative tool that can assist with clarification of Human Cells, Tissues and Cellular-Based Products (HCT/Ps) regulations under 21 CFR 1271 and Section 361 of the PHS Act and/or the FD&C Act

The goals of this project are to:

  • educate community regarding interpretation of GTP requirements and how best to prepare for FDA inspections of establishments that manufacture HCT/Ps
  • create a tool providing section-by-section guidance specific to the needs of a CT laboratory to achieve regulatory compliance and preparation for unannounced FDA inspections

To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Moderator & Speaker(s):
  • Lizette Caballero, MLS(ASCP), Senior Laboratory Supervisor , Janssen Pharmaceutical Companies of Johnson & Johnson
Speaker(s):
  • J. Wade Atkins, MS, MT(ASCP) SBB, CQA (ASQ), National Institutes of Health
  • Nadim Mahmud, MD, PhD, University of Illinois College of Medicine
Members: $20.00
Standard: $25.00